A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants
Latest Information Update: 05 Mar 2026
At a glance
- Drugs Apecotrep (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 19 Feb 2026 Status changed from not yet recruiting to recruiting.
- 04 Feb 2026 Planned initiation date changed from 31 Jan 2026 to 6 Feb 2026.
- 28 Jan 2026 Planned initiation date changed from 23 Jan 2026 to 31 Jan 2026.